Published in PLoS One on November 24, 2009
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res (2011) 1.14
Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS One (2010) 1.08
Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood (2011) 1.04
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS One (2011) 0.94
Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner. Mol Biol Cell (2012) 0.93
STAT5 in hematopoietic stem cell biology and transplantation. JAKSTAT (2013) 0.90
The gene encoding the hematopoietic stem cell regulator CCN3/NOV is under direct cytokine control through the transcription factors STAT5A/B. J Biol Chem (2010) 0.88
Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am J Pathol (2011) 0.87
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma (2014) 0.87
High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow. Blood (2011) 0.86
The expression of the glucocorticoid receptor in human erythroblasts is uniquely regulated by KIT ligand: implications for stress erythropoiesis. Stem Cells Dev (2012) 0.83
STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells. JAKSTAT (2012) 0.81
Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood (2001) 6.35
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell (1999) 4.69
Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A (2002) 3.50
SOCS proteins: negative regulators of cytokine signaling. Stem Cells (2001) 3.40
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32
STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J (1999) 3.14
Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev (2008) 2.68
Hematopoietic cytokine receptor signaling. Oncogene (2007) 2.13
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood (2002) 1.96
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood (2005) 1.93
Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia (2003) 1.85
Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood (2007) 1.81
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood (2008) 1.80
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev (2000) 1.61
Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood (2009) 1.58
Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci U S A (2007) 1.55
Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med (2004) 1.44
Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood (2006) 1.40
The role of STATs in myeloid differentiation and leukemia. Oncogene (2000) 1.34
Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol Cell Biol (2008) 1.33
Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol (2008) 1.32
Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells. Blood (2002) 1.25
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood (2007) 1.23
Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia (2001) 1.23
Aberrant cytokine signaling in leukemia. Oncogene (2007) 1.20
Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood (2007) 1.20
Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood (2008) 1.20
mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle (2005) 1.19
STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Exp Hematol (2007) 1.19
Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest (2008) 1.16
Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol (2007) 1.16
Flow-cytometric phosphoprotein analysis reveals agonist and temporal differences in responses of murine hematopoietic stem/progenitor cells. PLoS One (2008) 1.15
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells (2008) 1.14
STAT5 signaling in normal and pathologic hematopoiesis. Front Biosci (2007) 1.11
Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. Blood (2007) 1.08
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res (2008) 1.08
Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant (1999) 1.06
Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness. Blood (2003) 1.05
Ex vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells. Methods Mol Biol (2009) 1.03
Flow cytometric measurement of phosphorylated STAT5 in AML: lack of specific association with FLT3 internal tandem duplications. Leuk Res (2003) 1.02
Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol (2007) 1.02
Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis. Stem Cells (2008) 1.00
Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. Exp Hematol (2008) 0.96
STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha. Blood (2006) 0.91
Stem cell factor synergistically enhances thrombopoietin-induced STAT5 signaling in megakaryocyte progenitors through JAK2 and Src kinase. Stem Cells (2005) 0.84
Early-acting cytokine-driven ex vivo expansion of mobilized peripheral blood CD34+ cells generates post-mitotic offspring with preserved engraftment ability in non-obese diabetic/severe combined immunodeficient mice. Br J Haematol (2001) 0.80
Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet (2005) 6.91
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem (2002) 2.73
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med (2006) 2.18
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol (2005) 1.62
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1. Dev Cell (2003) 1.53
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation (2005) 1.48
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid (2002) 1.44
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica (2009) 1.39
Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood (2003) 1.39
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol (2007) 1.39
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood (2006) 1.39
Growth factor treatment prior to low-dose total body irradiation increases donor cell engraftment after bone marrow transplantation in mice. Blood (2002) 1.38
Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells (2005) 1.35
Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol Cell Biol (2008) 1.33
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica (2008) 1.33
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res (2006) 1.25
Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev (2004) 1.25
Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood (2009) 1.24
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood (2007) 1.23
ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol (2007) 1.21
Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer (2010) 1.21
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood (2010) 1.20
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica (2013) 1.19
Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. Blood (2002) 1.17
Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol (2007) 1.16
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood (2012) 1.15
All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood (2004) 1.14
A genetic and genomic analysis identifies a cluster of genes associated with hematopoietic cell turnover. Blood (2002) 1.13
Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. Blood (2011) 1.13
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol (2014) 1.13
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood (2013) 1.11
CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol (2003) 1.10
Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol (2003) 1.10
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica (2007) 1.09
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol (2013) 1.09
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica (2011) 1.09
Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. Blood (2007) 1.08
Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol (2009) 1.07
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 1.07
LIF-induced STAT3 signaling in murine versus human embryonal carcinoma (EC) cells. Exp Cell Res (2002) 1.07
Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity. J Immunol (2007) 1.07
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet (2006) 1.07
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood (2010) 1.06
Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia. J Leukoc Biol (2004) 1.05
Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors. Stem Cells (2005) 1.03
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood (2002) 1.03
Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells. Curr Opin Hematol (2010) 1.02
Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood (2004) 1.02
Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood (2007) 1.02
Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol (2007) 1.02
Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34+ cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis. Stem Cells (2008) 1.00
Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells. Exp Hematol (2006) 1.00
Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors. Blood (2009) 1.00
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol (2007) 1.00
Radionuclide imaging of bone marrow disorders. Eur J Nucl Med Mol Imaging (2010) 0.99
Fibroblast growth factor-1 and -2 preserve long-term repopulating ability of hematopoietic stem cells in serum-free cultures. Stem Cells (2006) 0.99
Plant sterols cause macrothrombocytopenia in a mouse model of sitosterolemia. J Biol Chem (2007) 0.98
Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. Biochem Pharmacol (2010) 0.98
Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail (2010) 0.97
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther (2004) 0.97